152 related articles for article (PubMed ID: 11581239)
1. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.
Wise R; Andrews JM; Ashby JP
J Antimicrob Chemother; 2001 Oct; 48(4):563-7. PubMed ID: 11581239
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
6. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
8. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
9. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001.
Critchley IA; Blosser-Middleton RS; Jones ME; Thornsberry C; Sahm DF; Karlowsky JA
Antimicrob Agents Chemother; 2003 May; 47(5):1689-93. PubMed ID: 12709341
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 May; 43(5):465-9. PubMed ID: 24636430
[TBL] [Abstract][Full Text] [Related]
11. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.
Critchley IA; Draghi DC; Sahm DF; Thornsberry C; Jones ME; Karlowsky JA
J Antimicrob Chemother; 2003 Mar; 51(3):639-49. PubMed ID: 12615866
[TBL] [Abstract][Full Text] [Related]
12. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
15. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).
Sader HS; Moet G; Jones RN
J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
Streit JM; Jones RN; Sader HS
J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
